X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare STRIDES PHARMA SCIENCE with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs SANOFI INDIA - Comparison Results

STRIDES PHARMA SCIENCE    Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE SANOFI INDIA STRIDES PHARMA SCIENCE/
SANOFI INDIA
 
P/E (TTM) x 51.7 38.5 134.4% View Chart
P/BV x 1.1 7.3 15.5% View Chart
Dividend Yield % 0.4 0.5 82.4%  

Financials

 STRIDES PHARMA SCIENCE   SANOFI INDIA
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
SANOFI INDIA
Dec-17
STRIDES PHARMA SCIENCE/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs1,1474,945 23.2%   
Low Rs6423,901 16.5%   
Sales per share (Unadj.) Rs317.21,081.8 29.3%  
Earnings per share (Unadj.) Rs7.8141.6 5.5%  
Cash flow per share (Unadj.) Rs25.1185.9 13.5%  
Dividends per share (Unadj.) Rs2.0033.00 6.1%  
Dividend yield (eoy) %0.20.7 30.0%  
Book value per share (Unadj.) Rs274.3868.8 31.6%  
Shares outstanding (eoy) m89.5023.03 388.6%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.84.1 69.0%   
Avg P/E ratio x114.031.2 364.9%  
P/CF ratio (eoy) x35.723.8 150.1%  
Price / Book Value ratio x3.35.1 64.1%  
Dividend payout %25.523.3 109.4%   
Avg Mkt Cap Rs m80,058101,862 78.6%   
No. of employees `0002.53.2 77.4%   
Total wages/salary Rs m4,3413,685 117.8%   
Avg. sales/employee Rs Th11,325.87,691.9 147.2%   
Avg. wages/employee Rs Th1,731.41,137.7 152.2%   
Avg. net profit/employee Rs Th280.11,006.5 27.8%   
INCOME DATA
Net Sales Rs m28,39424,914 114.0%  
Other income Rs m941807 116.6%   
Total revenues Rs m29,33425,721 114.0%   
Gross profit Rs m3,9655,372 73.8%  
Depreciation Rs m1,5401,022 150.7%   
Interest Rs m1,96211 17,840.0%   
Profit before tax Rs m1,4035,146 27.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-4360-   
Tax Rs m971,886 5.2%   
Profit after tax Rs m7023,260 21.5%  
Gross profit margin %14.021.6 64.8%  
Effective tax rate %6.936.6 18.9%   
Net profit margin %2.513.1 18.9%  
BALANCE SHEET DATA
Current assets Rs m24,83614,432 172.1%   
Current liabilities Rs m18,9936,010 316.0%   
Net working cap to sales %20.633.8 60.9%  
Current ratio x1.32.4 54.5%  
Inventory Days Days7161 116.5%  
Debtors Days Days11328 398.2%  
Net fixed assets Rs m34,2897,991 429.1%   
Share capital Rs m895230 388.6%   
"Free" reserves Rs m23,65119,778 119.6%   
Net worth Rs m24,54620,008 122.7%   
Long term debt Rs m15,5130-   
Total assets Rs m65,43727,770 235.6%  
Interest coverage x1.7468.8 0.4%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.40.9 48.4%   
Return on assets %4.111.8 34.6%  
Return on equity %2.916.3 17.6%  
Return on capital %6.925.8 26.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,6976,306 248.9%   
Fx outflow Rs m7355,257 14.0%   
Net fx Rs m14,9621,049 1,426.3%   
CASH FLOW
From Operations Rs m1,8714,351 43.0%  
From Investments Rs m5,826-787 -740.3%  
From Financial Activity Rs m-10,157-1,884 539.1%  
Net Cashflow Rs m-2,6151,680 -155.6%  

Share Holding

Indian Promoters % 27.7 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 37.8 14.4 262.5%  
FIIs % 8.6 14.6 58.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 10.5 246.7%  
Shareholders   56,241 15,184 370.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   WYETH LTD  PIRAMAL ENTERPRISES  ALEMBIC LTD  PANACEA BIOTECH  CADILA HEALTHCARE  

Compare STRIDES PHARMA SCIENCE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

From Urjit Patel to Shaktikanta Das; What Lies Ahead?(Podcast)

The week gone by saw Sensex plunge from 700 points to rise by over 600 points. With a volatile and eventful week, it was a challenge keeping up with the news every day.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY19); Net Profit Down 72.2% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 54 m (down 72.2% YoY). Sales on the other hand came in at Rs 7 bn (down 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

SANOFI INDIA Announces Quarterly Results (2QFY19); Net Profit Up 2.5% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, SANOFI INDIA has posted a net profit of Rs 1 bn (up 2.5% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

Are Foreign Investors Heading Back to the Indian Stock Markets?(Chart Of The Day)

Dec 3, 2018

After months of heavy FII selling, November witnessed a return on foreign money into Indian equities...

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Dec 14, 2018 (Close)

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE 5-YR ANALYSIS

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS